Designing Communities to Support Healthy Living in Aging Residents

November 28, 2023 updated by: University of Alberta
The Housing for Health team is making evidence-based recommendations to the developer and design team of an upcoming congregate-living development to support the healthy living of older adults who will be moving into the new building. There may also be opportunities to improve the surrounding neighbourhood by collaborating with the municipality where the development is located. We will evaluate whether the intervention leads to changes in the perceived, micro-scale, and macro-scale physical built environment (BE), and whether there are impacts on the physical activity (PA), healthy eating, and social connections of residents. In parallel, we will gather qualitative data to provide a more in-depth understanding of how the BE may facilitate or hinder resident's healthy living behaviours.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Background: The Housing for Health team is making evidence-based recommendations to the developer and design team of an upcoming congregate-living development to support the healthy living of older adults who will be moving into the new building. There may also be opportunities to improve the surrounding neighbourhood by collaborating with the municipality where the development is located. We will evaluate whether the intervention leads to changes in the perceived, micro-scale, and macro-scale physical built environment (BE), and whether there are impacts on the physical activity (PA), healthy eating, and social connections of residents. In parallel, we will gather qualitative data to provide a more in-depth understanding of how the BE may facilitate or hinder resident's healthy living behaviours.

Methods: This project employs a quasi-experimental pre-post design. The quantitative built environment (BE) evaluation includes assessments of macroscale (e.g., layout of communities) and microscale (e.g., street details and characteristics) changes as measured using Geographical Information Systems (GIS) and Microscale Audit Pedestrian Streetscapes (MAPS) audits, respectively. For the quantitative resident evaluation, residents moving into the intervention site or who currently live at a control site will be invited to participate. Study outcomes will be measured using self-report (i.e., surveys) and objective tools (i.e., accelerometers, Global Positioning System). The qualitative resident-environment component will be conducted using in-depth semi-structured interviews with building residents, family members, and stakeholders involved in the design/development and/or operation of the intervention site and others living in the developments' neighbourhoods. Participant observations will be completed in the building and neighbourhood environments of the intervention site.

Discussion: Findings will provide evidence on whether and how comprehensive changes to the BE of a building, site, and/or neighbourhood of a congregate living facility can impact PA, healthy eating, and social connections of older adults. Successful aspects of interventions will be scaled up in future work. We will disseminate findings to a broad audience including the scientific community via peer-reviewed publications, conference presentations, and discussion panels; and private, public, and non-profit sectors via reports, public presentations and/or communications via our partners and their networks.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
155

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Canada
    • Alberta
      • Edmonton, Alberta, Canada, T6G 2C8
        • University of Alberta

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 110 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Men or women aged 18 years or older that are either moving into the intervention site(s), or living in a control site.

Exclusion Criteria:

  • Residents who have been told by a health care provider that they have Alzheimer's or dementia.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Residents moving into a congregate-living development with more features that support healthy living
Residents moving into a congregate-living development designed for older adults with more design and amenities features in the building, site, and/or neighbourhood that support physical activity, healthy eating, and social connections.
Behavioral: Residents moving into a congregate-living development with more features that support healthy living
Our team is making evidence-based recommendations to the developer and design team of an upcoming congregate-living development to support the physical activity, healthy eating, and social connections of residents moving into the new building(s). We hope for the developer to integrate into the new building(s) as many as possible of our team's built environment design and amenity recommendations into their site and/or building plans. Additionally, discussions with the municipality are also occuring on built environment design and amenity recommendations to improve the neighbourhood surrounding the site. Although our team has provided these recommendations, it is ulimatily up to the discretion of the developer and the municipality as to whether and what design and amenity changes are made.
No Intervention: Residents living in a standard congregate-living development
Residents living in a standard community-based congregate-living development designed for older adults.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in self-reported physical activity from baseline to 3-6-months post-move-in
Time Frame: baseline and 3-6-months post-move-in
Self-reported physical activity will be adapted from the Neighborhood - International Physical Activity Questionnaire (N-IPAQ)
baseline and 3-6-months post-move-in
Change in self-reported physical activity from baseline to 9-12-months post-move-in
Time Frame: baseline and 9-12-months post-move-in
Self-reported physical activity will be adapted from the Neighborhood - International Physical Activity Questionnaire (N-IPAQ)
baseline and 9-12-months post-move-in
Change in accelerometer-measured physical activity from baseline to 9-12-months post-move-in
Time Frame: baseline and 9-12-months post-move-in
Accelerometer-measured physical activity will be measured using Actigraph accelerometers.
baseline and 9-12-months post-move-in
Change in accelerometer-measured physical activity from baseline to 3-6-months post-move-in
Time Frame: baseline and 3-6-months post-move-in
Accelerometer-measured physical activity will be measured using Actigraph accelerometers.
baseline and 3-6-months post-move-in
Change in location-measured physical activity from baseline to 3-6-months post-move-in
Time Frame: baseline and 3-6-months post-move-in
Location-measured physical activity will be measured using Qstarz Travel Recorder Geographical Positioning System (GPS) devices.
baseline and 3-6-months post-move-in
Change in location-measured physical activity from baseline to 9-12-months post-move-in
Time Frame: baseline and 9-12-months post-move-in
Location-measured physical activity will be measured using Qstarz Travel Recorder Geographical Positioning System (GPS) devices.
baseline and 9-12-months post-move-in
Change in healthy eating from baseline to 3-6-months post-move-in
Time Frame: baseline and 3-6-months post-move-in
Healthy eating will be adapted from the Nutritional Environment Measures Survey - Perceived Nutrition Environment (NEMS-P)
baseline and 3-6-months post-move-in
Change in healthy eating from baseline to 9-12-months post-move-in
Time Frame: baseline and 9-12-months post-move-in
Healthy eating will be adapted from the Nutritional Environment Measures Survey - Perceived Nutrition Environment (NEMS-P)
baseline and 9-12-months post-move-in
Change in unhealthy eating from baseline to 3-6-months post-move-in
Time Frame: baseline and 3-6-months post-move-in
Unhealthy eating will be adapted from the Nutritional Environment Measures Survey - Perceived Nutrition Environment (NEMS-P)
baseline and 3-6-months post-move-in
Change in unhealthy eating from baseline to 9-12-months post-move-in
Time Frame: baseline and 9-12-months post-move-in
Unhealthy eating will be adapted from the Nutritional Environment Measures Survey - Perceived Nutrition Environment (NEMS-P)
baseline and 9-12-months post-move-in
Change in social connections from baseline to 3-6-months post-move-in
Time Frame: baseline and 3-6-months post-move-in
Social connections will be derived from several self-report items.
baseline and 3-6-months post-move-in
Change in social connections from baseline to 9-12-months post-move-in
Time Frame: baseline and 9-12-months post-move-in
Social connections will be derived from several self-report items.
baseline and 9-12-months post-move-in
Change in the micro-scale built environment from baseline to 3-6-months post-move-in
Time Frame: baseline and 3-6-months post-move-in
The actual micro-scale built environment is measured using the Microscale Audit of Pedestrian Streetscapes (MAPS) audit tool
baseline and 3-6-months post-move-in
Change in the micro-scale built environment from baseline to 9-12-months post-move-in
Time Frame: baseline and 9-12-months post-move-in
The actual micro-scale built environment is measured using the Microscale Audit of Pedestrian Streetscapes (MAPS) audit tool
baseline and 9-12-months post-move-in
Change in the macro-scale built environment from baseline to 3-6-months post-move-in
Time Frame: baseline and 3-6-months post-move-in
The actual macro-scale built environment is measured using Geographical Information Systems (GIS)
baseline and 3-6-months post-move-in
Change in the macro-scale built environment from baseline to 9-12-months post-move-in
Time Frame: baseline and 9-12-months post-move-in
The actual macro-scale built environment will be measured using Geographical Information Systems (GIS)
baseline and 9-12-months post-move-in
Change in the perceived neighbourhood built environment from baseline to 3-6-months post-move-in
Time Frame: baseline and 3-6-months post-move-in
The perceived neighbourhood built environment will be measured using the Physical Activity Neighborhood Environment Scale (PANES)
baseline and 3-6-months post-move-in
Change in the perceived neighbourhood built environment from baseline to 9-12-months
Time Frame: baseline and 9-12-months post-move-in
The perceived neighbourhood built environment will be measured using the Physical Activity Neighborhood Environment Scale (PANES)
baseline and 9-12-months post-move-in
Change in the perceived neighbourhood food environment from baseline to 3-6-months
Time Frame: baseline and 3-6-months post-move-in
The perceived neighbourhood food environment will be measured using the Nutritional Environment Measures Survey - Perceived Nutrition Environment (NEMS-P)
baseline and 3-6-months post-move-in
Change in the perceived neighbourhood food environment from baseline to 9-12-months
Time Frame: baseline and 9-12-months post-move-in
The perceived neighbourhood food environment will be measured using the Nutritional Environment Measures Survey - Perceived Nutrition Environment (NEMS-P)
baseline and 9-12-months post-move-in

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Alberta

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
University of Alberta, Physical Education

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 1, 2021

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 26, 2023

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
September 26, 2023

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 29, 2021

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 26, 2021

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 1, 2021

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 29, 2023

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 28, 2023

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2023

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 1819-HQ-000051

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Aging

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings